XML 27 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
shares in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 12, 2015
Sep. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Jun. 30, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Available-for-sale securities, fair values   $ 7,512,000 $ 7,512,000   $ 7,512,000   $ 5,000,000  
Fair value of plan assets   1,142,000 1,142,000   1,142,000   1,234,000  
Prepaid royalties               $ 1,100,000
Accumulated depreciation of property and equipment   33,252,000 33,252,000   33,252,000   31,416,000  
Amount of goodwill at period end   18,974,000 18,974,000   $ 18,974,000   21,734,000  
Expiration date of rights agreement         Dec. 31, 2019      
Revenue recognition, milestone method description         We may be eligible to receive additional milestone payments. These payments would be based upon the aggregate number of new patients enrolled in the patient care database, in a given calendar year, after exceeding a baseline threshold, and could range from $3,500 to $55,500 annually over the term of the agreement. The first performance-based milestone period ends on December 31, 2015,      
Maximum value of contract revenue from clinical and regulatory activities $ 10,400,000              
Initial contract revenue from clinical and regulatory activities 1,800,000              
Remaining contract revenue from clinical and regulatory activities $ 8,600,000              
Period of contract 3 years              
Additional contract revenue from clinical and regulatory activities   7,200,000            
Reserve for sales return and allowances         $ 277,000   437,000  
Deferred revenue   13,302,000 $ 13,302,000   $ 13,302,000   8,043,000  
Number of anti-dilutive securities excluded from EPS computation     6,231 2,647 4,648 3,313    
Accumulated foreign currency adjustments included in other comprehensive loss amounted   6,036,000 $ 6,036,000 $ 2,451,000 $ 6,036,000 $ 2,451,000    
Up Front Payment Arrangement [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Deferred revenue   953,000 953,000   953,000   613,000  
AbbVie [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Deferred revenue   12,349,000 $ 12,349,000   $ 12,349,000   $ 7,430,000  
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Percentage of concentration risk     11.00%       0.00%  
Customer Two [Member] | Net Revenue [Member] | Customer Concentration Risk [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Percentage of concentration risk     11.00% 12.00% 12.00% 0.00%    
Guaranteed Investment Certificates [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Available-for-sale securities, amortized cost   7,512,000 $ 7,512,000   $ 7,512,000   $ 7,512,000  
Available-for-sale securities, fair values   $ 5,000,000 5,000,000   5,000,000   $ 5,000,000  
Other [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Exclusivity payments recognized in lieu of sale of exclusive rights     3,397,000          
Contract revenues from clinical and regulatory activities     $ 750,000          
Maximum [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Payments received for sale of exclusive rights         75,000,000      
Additional annual payments to be received for sale of exclusive rights         $ 55,500,000      
Maximum [Member] | Buildings [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         40 years      
Maximum [Member] | Computer Equipment [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         10 years      
Maximum [Member] | Machinery and Equipment [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         10 years      
Maximum [Member] | Furniture and Fixtures [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         10 years      
Minimum [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Additional annual payments to be received for sale of exclusive rights         $ 3,500,000      
Minimum [Member] | Buildings [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         20 years      
Minimum [Member] | Computer Equipment [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         2 years      
Minimum [Member] | Machinery and Equipment [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         2 years      
Minimum [Member] | Furniture and Fixtures [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Estimated useful lives of assets         2 years      
DNA Genotek [Member]                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Number of third-party suppliers to manufacture DNAG's products         2